In 71 Surmount V participants over 50, epigenetic clocks moved slower than calendar time. Duffin credits weight loss for most of it, and experts warn against overreading the results.
Recap by typeshit. Full story at CNN.
The study of over 87,000 matched patients 65 and up also found 28% fewer liver decompensation events, but no drop in heart attack or stroke and more osteoporosis diagnoses.
18:05
Dr. Stirrett walks through three pointers for people on tirzepatide, framed as part of a broader GLP-1 guide. His advice, not a set protocol.
He walks through an Azoury et al study in the October 2026 Plastic and Reconstructive Surgery that uses global health network data to compare the two weight loss routes.
The claim credits GLP-1 drugs' effects on insulin sensitivity and inflammation for changes in dermatologic conditions. No study is cited.
In a 575-user study across four countries, 39% reported nails lifting versus 9% of controls. A companion study also found more hair loss and scalp redness.
Gallup estimates 11% of US adults used GLP-1s for weight loss in 2026, up from 3% in 2024, and food makers are reworking protein, fiber and portion sizes.
Loading…